Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Massarotti

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Science (New York, N.Y.)|January 30, 2010
Platelets amplify inflammation in arthritis via collagen-dependent microparticle productionEric Boilard, Peter A Nigrovic, Katherine Larabee, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2019
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus ErythematosusRosalind Ramsey-Goldman, Roberta Vezza Alexander, Elena M Massarotti, et al.
ACR Open Rheumatology|February 4, 2021
A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified LupusRosalind Ramsey-Goldman, Roberta Vezza Alexander, John Conklin, et al.
Annals of the Rheumatic Diseases|July 3, 2026
PD-1 signalling restrains pathogenic T peripheral helper and effector CD4⁺ T cell functions in rheumatoid arthritisKazuhiko Higashioka, John M Sowerby, Kathryne E Marks, et al.
International Journal of Immunopathology and Pharmacology|June 10, 2009
The safety of anti-TNF agents in the elderlyA Migliore, E Bizzi, B Laganà, et al.
Rheumatology (Oxford, England)|August 28, 2012
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb studyMichael E Weinblatt, Roy Fleischmann, Tom W J Huizinga, et al.
Clinical and Experimental Rheumatology|June 7, 2011
Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO)S Adami, D Maugeri, V Toscano, et al.
The Oncologist|May 16, 2019
Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent CancerChristopher S Nabel, Mariano Severgnini, Yin P Hung, et al.
EMBO Molecular Medicine|May 1, 2010
A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritisEric Boilard, Ying Lai, Katherine Larabee, et al.
The Lancet. Rheumatology|January 31, 2025
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort studyKathleen M M Vanni, Kaitlin R McCarter, Xiaosong Wang, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Science (New York, N.Y.)|January 30, 2010
Platelets amplify inflammation in arthritis via collagen-dependent microparticle productionEric Boilard, Peter A Nigrovic, Katherine Larabee, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2019
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus ErythematosusRosalind Ramsey-Goldman, Roberta Vezza Alexander, Elena M Massarotti, et al.
ACR Open Rheumatology|February 4, 2021
A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified LupusRosalind Ramsey-Goldman, Roberta Vezza Alexander, John Conklin, et al.
Annals of the Rheumatic Diseases|July 3, 2026
PD-1 signalling restrains pathogenic T peripheral helper and effector CD4⁺ T cell functions in rheumatoid arthritisKazuhiko Higashioka, John M Sowerby, Kathryne E Marks, et al.
International Journal of Immunopathology and Pharmacology|June 10, 2009
The safety of anti-TNF agents in the elderlyA Migliore, E Bizzi, B Laganà, et al.
Rheumatology (Oxford, England)|August 28, 2012
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb studyMichael E Weinblatt, Roy Fleischmann, Tom W J Huizinga, et al.
Clinical and Experimental Rheumatology|June 7, 2011
Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO)S Adami, D Maugeri, V Toscano, et al.
The Oncologist|May 16, 2019
Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent CancerChristopher S Nabel, Mariano Severgnini, Yin P Hung, et al.
EMBO Molecular Medicine|May 1, 2010
A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritisEric Boilard, Ying Lai, Katherine Larabee, et al.
The Lancet. Rheumatology|January 31, 2025
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort studyKathleen M M Vanni, Kaitlin R McCarter, Xiaosong Wang, et al.
Pageof 8